Skip to main content
. 2020 Apr 1;19(6):3859–3870. doi: 10.3892/ol.2020.11502

Figure 3.

Figure 3.

Genetic alterations prior to first- or second-generation EGFR-tyrosine kinase inhibitors treatment based on next-generation sequencing targeting 59 genes from 41 patients with advanced non-small cell lung cancer harboring EGFR mutation. EGFR, epidermal growth factor receptor; PR, partial response; SD, stable disease; PD, progressive disease; VAF, variant allele frequency.